OTCQB
Every company in the roster listed on OTCQB.
Every company in the roster listed on OTCQB.
2 of 2 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
CytoDynCYDY · OTCQB | 1 asset: 1 Ph 3 | LeronlimabPhase 2/3 · HIVPartial signal | Jan 2028Leronlimab · Phase 2 | —no price since 18 Aug 2026 | $16MAug 2026 | ~3.3 qtrs | $7.2M |
Emmaus Life SciencesEMMA · OTCQB | 1 asset: 1 approved | Approved assets only | None on record | — | $2.8MJun 2026 | Cash-flow positive | $0.2M |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.